title: DOCK4 deletion at 7q31.1 in a de novo acute myeloid leukemia with a normal karyotype.
abstract: BACKGROUND
  Acute myeloid leukemia with a normal karyotype (NK-AML) has been assigned to an intermediate prognostic risk group. However, there is a marked variability in outcome within this group of AML, suggesting a significant biological and molecular heterogeneity. Chromosomal abnormalities may be cryptic by metaphase cytogenetics, but still have an impact on the process of leukemogenesis and/or the clinical outcome of NK-AML. Therefore, we analyzed the genomic complement of NK-AML cases to search for the presence of submicroscopic genomic imbalances.
  
  
  METHODS
  We applied high-resolution oligo-based aCGH analysis to a cohort of AML patients with a normal karyotype, and FISH to validate the aCGH findings. Relative gene expression levels were examined by qPCR.
  
  
  RESULTS
  High-resolution aCGH analysis of 21 NK-AML patients revealed one patient with a rare submicroscopic deletion at 7q31.1. This female patient exhibited a rapid disease progression and a dismal outcome. The deletion was mono-allelic, approximately 189,1 kb in size, and encompassed the major 3' part of the DOCK4 gene. The expression level of the DOCK4 gene in her leukemic cells was decreased when compared to CD34+ cells from healthy controls. When compared to AML patients with -7/del(7q) as the sole chromosomal anomaly, the DOCK4 expression level was found to be similarly low.
  
  
  CONCLUSIONS
  This is the first report of an acquired partial deletion of the DOCK4 gene in a patient with de novo NK-AML. DOCK4 is a strong tumor suppressor candidate, required for GTPase activation in signal transduction pathways controlling cellular proliferation, adhesion, migration and phagocytosis. Our findings may be relevant for understanding of the process of leukemogenesis and the response to therapy in a subset of NK-AML patients.
authors: Hemodiagnostic Laboratory, Cancer Cytogenetics Section, Department of Hematology, Aarhus University Hospital, Tage-Hansens Gade 2, Ent. 4A, 8000, Aarhus C, Denmark, Eigil.Kjeldsen@ki.au.dk.
authors: Eigil
authors: E
authors: Kjeldsen
authors: Christopher
authors: C
authors: Veigaard
mesh_terms: D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D005260:Female; D020690:GTPase-Activating Proteins / Q000235:genetics*; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D008875:Middle Aged
chemical_list: C510122:DOCK4 protein, human; D020690:GTPase-Activating Proteins
references: J Biol Chem. 2011 Jul 15;286(28):25211-23
references: 21532034
references: Exp Cell Res. 2006 Dec 10;312(20):4205-16
references: 17027967
references: Leuk Res. 2013 Apr;37(4):416-21
references: 23337401
references: Nat Cell Biol. 2002 Aug;4(8):E188-90
references: 12149627
references: Haematologica. 2004 Sep;89(9):1082-90
references: 15377469
references: Genes Chromosomes Cancer. 1999 Aug;25(4):384-92
references: 10398433
references: Blood. 1997 Mar 15;89(6):2079-88
references: 9058730
references: Haematologica. 2003 Apr;88(4):429-37
references: 12681970
references: Leuk Res. 2001 Sep;25(9):735-9
references: 11489466
references: Cancer Genet. 2011 Apr;204(4):187-94
references: 21536236
references: Eur J Haematol. 2004 Jun;72(6):390-402
references: 15128417
references: Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3781-5
references: 9520444
references: Br J Haematol. 1996 Mar;92(3):574-81
references: 8616020
references: J Cell Biol. 2010 Aug 9;190(3):461-77
references: 20679435
references: Eur J Haematol. 2008 Aug;81(2):112-22
references: 18410541
references: Curr Oncol Rep. 2012 Oct;14(5):359-68
references: 22806102
references: Biochim Biophys Acta. 2009 Apr;1788(4):790-6
references: 19159611
references: Oncogene. 1994 Oct;9(10):2817-25
references: 8084587
references: Cancer Genet Cytogenet. 2004 Apr 15;150(2):136-43
references: 15066321
references: Blood. 2010 Feb 4;115(5):936-47
references: 19965643
references: Avicenna J Med Biotechnol. 2009 Jul;1(2):117-23
references: 23407849
references: Mol Cytogenet. 2011 Jan 20;4:3
references: 21251322
references: Blood. 1997 Mar 15;89(6):2036-41
references: 9058725
references: Cancer Genet Cytogenet. 2005 Oct 15;162(2):151-9
references: 16213364
references: Br J Haematol. 1996 Apr;93(1):75-80
references: 8611479
references: Leuk Res. 2010 Apr;34(4):447-53
references: 19758696
references: Oncogene. 2008 Oct 2;27(44):5845-55
references: 18641688
references: J Cell Sci. 2002 Dec 15;115(Pt 24):4901-13
references: 12432077
references: Blood. 1989 Jan;73(1):230-4
references: 2562922
references: Blood. 1996 Sep 15;88(6):1930-5
references: 8822909
references: Trends Cell Biol. 2007 Aug;17(8):383-93
references: 17765544
references: Cell. 2003 Mar 7;112(5):673-84
references: 12628187
references: Blood. 1998 Dec 1;92(11):4031-5
references: 9834205
references: Leukemia. 2007 Mar;21(3):571-4
references: 17268525
references: Mol Cell Biol. 2009 Aug;29(16):4508-18
references: 19528233
references: Blood. 2010 Jul 22;116(3):354-65
references: 20385793
references: Blood. 2007 Jan 15;109(2):431-48
references: 16960150
references: Mol Cytogenet. 2012 May 01;5(1):21
references: 22548894
references: Blood. 2013 Feb 7;121(6):975-83
references: 23212519
references: Leuk Res. 2007 Apr;31(4):477-82
references: 17064770
references: Curr Opin Hematol. 2001 Jul;8(4):189-91
references: 11561153
references: J Clin Oncol. 2013 Mar 20;31(9):1172-81
references: 23382473
references: Blood. 1996 May 1;87(9):3579-86
references: 8611680
references: Curr Opin Hematol. 2007 Mar;14(2):106-14
references: 17255787